The efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism

被引：3

作者：

Chen, MC ^{[1
]}

Hu, CT

Wang, LY

Lin, HH

机构：

[1] Buddhist Tzu Chi Gen Hosp, Dept Gastroenterol, Hualien, Taiwan

[2] Tzu Chi Univ, Hualien, Taiwan

[3] Res Ctr Hepatol, Hualien, Taiwan

来源：

ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2005年 / 22卷 / 03期

关键词：

D O I：

10.1111/j.1365-2036.2005.02545.x

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

收藏

页码：274 / 275

页数：4

相关论文

共 5 条

[1] CHEN MC, 2005, GASTROENTEROLOGICAL, V22, P86
[2] Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations
Goldstein, JA
Ishizaki, T
Chiba, K
deMorais, SMF
Bell, D
Krahn, PM
Evans, DAP
[J]. PHARMACOGENETICS, 1997, 7 (01): : 59 - 64
[3] HEDRICK PW, 2000, GENETICS POPULATIONS, P47
[4] Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism
Sheu, BS
Kao, AW
Cheng, HC
Hunag, SF
Chen, TW
Lu, CC
Wu, JJ
[J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (03) : 283 - 288
[5] Genetic variations of S-mephenytoin 4′-hydroxylase (CYP2C19) in the Chinese population
Xie, HG
[J]. LIFE SCIENCES, 2000, 66 (14) : PL175 - PL181